It's no secret that cell and gene therapies have faced manufacturing hurdles as the advanced medicines have become increasingly popular in recent years. Now, the FDA is proposing to work directly with industry through a series of facility tours that could enable both sides to learn something from each other.
In a federal register post Monday, the Office of Therapeutic Products (OTP) of the FDA’s Center for Biologics Evaluation and Research (CBER) unveiled its Cellular and Gene Therapies Interactive Site Tours Program. The initiative is designed to let CBER project managers and reviewers swap regulatory know-how with their industry counterparts on-site.
CBER hopes the program will bolster its review skills by providing agency staffers with a better understanding of the biotechnology manufacturing industry and its operations, according to the post.
The goal of the program, which cell and gene therapy manufacturers are being invited to volunteer for by August 14, is twofold: grant CBER and OTP staffers “firsthand exposure” to the industry’s product development processes; and create a venue for sharing information about project management best practices with industry representatives.
Polymer Vial for cell and gene therapies
RTU(ready to use) 2ml COP vial
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
MAKE AN ENQUIRY
